Comparing the current results to its competitors, Cogent Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 16.57 %, recorded in the same quarter.
Cogent Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 500.67 %
April 9, 2024
The realm of cancer therapeutics is ever-expanding with groundbreaking research constantly contributing to novel strategies and interventions, striving to enhance clinical outcomes. Prominent in this arena is the development of targeted therapies, including ErbB2 inhibitors, which have revolutionized treatment paradigms for specific cancer subtypes. This article enunciates the burgeoning discoveries and the potential implications emanating from the research conducted by Cogent Biosciences, about their novel, highly potent, and selective CNS-penetrant ErbB2 inhibitor.ErbB2, also known as human epidermal growth factor receptor 2 (HER2), is a member of the epidermal growth factor receptor (EGFR) family, signify...
February 14, 2024
Cogent Biosciences, a leading biotechnology company focusing on the development of precision therapies for genetically driven diseases, has recently announced the completion of an oversubscribed private placement, raising an impressive $225 million. This significant financial boost is expected to support the company through its ongoing registration-directed clinical trials, which include the SUMMIT, PEAK, and APEX studies. With pro-forma cash, cash equivalents, and marketable securities projected to fund Cogent into 2027, this considerable investment brings promising implications for the company s future success.BodyCogent Biosciences has made great strides in the world of gene-targeted therapies, and this r...
Inozyme Pharma Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapies for the treatment of rare and life-threatening mineral metabolic disorders. The company aims to leverage its expertise in the biology of enzymes and rare diseases to develop innovative therapeutics that can address the underlying cause of these disorders. Inozyme Pharma pursues partnerships and collaborations to advance their pipeline of potential therapies and bring them to market efficiently.
Werewolf Therapeutics Inc operates with a business model focused on utilizing innovative technologies to develop therapies targeting cancer using immune cell activation.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Sources:
Cogent Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cogent Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
